全文获取类型
收费全文 | 6027篇 |
免费 | 490篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 234篇 |
妇产科学 | 162篇 |
基础医学 | 815篇 |
口腔科学 | 90篇 |
临床医学 | 823篇 |
内科学 | 1118篇 |
皮肤病学 | 273篇 |
神经病学 | 482篇 |
特种医学 | 256篇 |
外科学 | 796篇 |
综合类 | 182篇 |
一般理论 | 6篇 |
预防医学 | 632篇 |
眼科学 | 50篇 |
药学 | 319篇 |
中国医学 | 5篇 |
肿瘤学 | 284篇 |
出版年
2023年 | 44篇 |
2022年 | 59篇 |
2021年 | 163篇 |
2020年 | 86篇 |
2019年 | 130篇 |
2018年 | 159篇 |
2017年 | 117篇 |
2016年 | 158篇 |
2015年 | 159篇 |
2014年 | 192篇 |
2013年 | 266篇 |
2012年 | 306篇 |
2011年 | 397篇 |
2010年 | 185篇 |
2009年 | 190篇 |
2008年 | 236篇 |
2007年 | 249篇 |
2006年 | 251篇 |
2005年 | 252篇 |
2004年 | 211篇 |
2003年 | 188篇 |
2002年 | 180篇 |
2001年 | 112篇 |
2000年 | 126篇 |
1999年 | 141篇 |
1998年 | 116篇 |
1997年 | 83篇 |
1996年 | 98篇 |
1995年 | 81篇 |
1994年 | 82篇 |
1993年 | 64篇 |
1992年 | 110篇 |
1991年 | 84篇 |
1990年 | 97篇 |
1989年 | 93篇 |
1988年 | 114篇 |
1987年 | 67篇 |
1986年 | 78篇 |
1985年 | 53篇 |
1984年 | 82篇 |
1983年 | 59篇 |
1982年 | 55篇 |
1981年 | 44篇 |
1980年 | 41篇 |
1979年 | 35篇 |
1978年 | 32篇 |
1974年 | 30篇 |
1973年 | 43篇 |
1972年 | 27篇 |
1967年 | 28篇 |
排序方式: 共有6551条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
5.
D Monnier† C Vidal‡ L Martin§ A Danzon¶ F Pelletier† E Puzenat† MP Algros†† D Blanc† R Laurent† PH Humbert† F Aubin† 《Journal of the European Academy of Dermatology and Venereology》2006,20(10):1237-1242
BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a rare malignant tumour of the skin, with an estimated incidence of 0.8 to five cases per 1 million people per year. OBJECTIVE: To study epidemiological, immunohistochemical and clinical features, delay in diagnosis, type of treatment and outcome of DFSP from 1982 to 2002. METHODS: Using data from the population-based cancer registry, 66 patients with pathologically proved DFSP were included (fibrosarcomatous DFSP were excluded). Each patient lived in one of the four departments of Franche-Comté (overall population of 1 million people) at the time of diagnosis. The main data sources came from public and private pathology laboratories and medical records. The rules of the International Agency for Research on Cancer were applied. RESULTS: The estimated incidence of DFSP in Franche-Comté was about three new cases per 1 million people per year. Male patients were affected 1.2 times as often as female patients were. The trunk (45%) followed by the proximal extremities (38%) were the most frequent locations. DFSP occurred mainly in young adults between 20 and 39 years of age. Mean age at diagnosis was 43 years, and the mean delay in diagnosis was 10.08 years. Our 66 patients initially underwent a radical local excision. Among them, 27% experienced one or more local recurrences during 9.6 years of follow-up. There was one regional lymph node recurrence without visceral metastases. These recurrences were significantly related to the initial peripheral resection margins. We observed a local recurrence rate of 47% for margins less than 3 cm, vs. only 7% for margins ranging from 3 to 5 cm [P=0.004; OR=0.229 (95%, CI=0.103-0.510)]. The mean time to a first local recurrence was 2.65 years. Nevertheless, there was no death due to the DFSP course at the end of the follow-up, and the final outcome was favourable. CONCLUSION: Our study emphasizes the importance of wide local excision with margins of at least 3 cm in order to prevent local recurrence. However, the recent development of inhibitors of signal transduction by the PDGFB pathway should soon modify the surgical strategy, which is often too mutilating. 相似文献
6.
7.
8.
9.
10.